Motivational Interviewing to Prevent Suicide in High Risk Veterans

Suicidal Ideation Clinical Trial

Official title:

Motivational Interviewing to Prevent Suicide in High Risk Veterans

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01544127
• Other study ID #: MHBA-20-11S
• Secondary ID: IK2CX00064
• Status: Completed
• Phase: N/A
• Start date: July 30, 2012
• Est. completion date: December 5, 2017

Study information

• Verified date: February 2022
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of study is to test the efficacy of an adaptation of Motivational Interviewing to Address Suicidal Ideation (MI-SI) on the severity of suicidal ideation in psychiatrically hospitalized Veterans at high risk for suicide.

Description:

Veterans who receive health care from the VA are at elevated risk for suicide, and the number of Veterans at high risk may be growing. Although the months following discharge from psychiatric hospitalization are a period of acute risk for Veterans, there is a dearth of empirically supported treatments tailored to psychiatric inpatients and no studies examining treatments for psychiatrically hospitalized Veterans. This randomized controlled trial will test the efficacy of an adaptation of Motivational Interviewing to Address Suicidal Ideation (MI-SI) on the severity of suicidal ideation in psychiatrically hospitalized Veterans at high risk for suicide. Participants will be recruited from the Acute Psychiatric Inpatient Unit at the Syracuse VA Medical Center. To meet high-risk criteria, Veterans must score over two on the Scale for Suicidal Ideation (SSI), which is prospectively predictive of death by suicide. Participants will complete a screening assessment to confirm eligibility and a baseline assessment of risk factors for suicide. They will be randomized to receive Motivational Interviewing to Address Suicidal Ideation (MI-SI) or a revised version (MI-SI-R) plus treatment as usual (TAU), or TAU alone. The MI-SI groups will receive two sessions of MI-SI during hospitalization and one telephone booster session after discharge. Participants in all conditions will be asked to complete telephone follow-up interviews at 1, 3, and 6 months after discharge. Change in the severity of suicidal ideation will be measured using the SSI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 132
• Est. completion date: December 5, 2017
• Est. primary completion date: December 5, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Veteran status,

• admitted to psychiatric inpatient unit,

• age 18 and over,

• English speaking,

• able to understand the study and provide informed consent,

• clinically cleared to participate by unit staff,

• receive health care from a VHA facility in upstate New York

• at increased risk for suicide (Scale for Suicidal Ideation [SSI] > 2)

Exclusion Criteria:

• current psychosis,

• current mania,

• dementia,

• prisoner status,

• being inaccessible

• being discharged from the unit less than 48 hours after being identified by study staff

Related Conditions & MeSH terms

• Suicidal Ideation
• Suicide
• Treatment Engagement

Intervention

Behavioral:
• MI-SI+TAU
MI-SI focuses on exploring and resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
• MI-SI-R+TAU
MI-SI-R focuses on resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)

Other:
• TAU Alone
Inpatient treatment includes medication management, case management, meals and a bed, milieu therapy consisting of creative and social activities, and a safety plan. Some families of veterans also received education to create a supportive home environment. As part of Veterans Health Administration (VHA) suicide prevention policy, the care of suicidal patients is also overseen by a local Suicide Prevention Coordinator and case managers.

Locations

Country	Name	City	State
United States	Syracuse VA Medical Center, Syracuse, NY	Syracuse	New York

Sponsors (1)

Lead Sponsor	Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Participants With a Suicide Attempt	Presence of a suicide attempt was measured with the Columbia Suicide Severity Rating Scale (C-SSRS) at 1, 3, and 6 months after discharge.	1, 3, and 6 months
Primary	Number of Participants With Suicidal Ideation	The number of participants with suicidal ideation and severity of suicidal ideation was measured using the Scale for Suicidal Ideation (SSI) at 1, 3, and 6 months after discharge. Scores range from 0-38, with scores of 1 or greater indicating the presence of suicidal ideation.	6 months
Primary	Severity of Suicidal Ideation Among Those With It	Severity of suicidal ideation was measured by the Scale for Suicidal Ideation at 1, 3, and 6 months after discharge. Scores range from 0 to 38, with higher scores indicating more severe suicidal ideation.	6 months
Secondary	Number of Participants With Two Outpatient Mental Health or Substance Treatment Sessions	Treatment engagement was measured using the Treatment Services Review-6 (TSR-6) at 1 month after discharge.	1 month